You can buy or sell Evoke Pharma and other stocks, options, ETFs, and crypto commission-free!
Evoke Pharma, Inc. Common Stock, also called Evoke Pharma, is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. Read More It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.
Solana Beach, California
52 Week High
52 Week Low
Simply Wall StMar 13
Could Evoke Pharma, Inc.’s (NASDAQ:EVOK) Investor Composition Influence The Stock Price?
If you want to know who really controls Evoke Pharma, Inc. (NASDAQ:EVOK), then you’ll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, ‘Don’t tell me what you think, tell me what you have in your portfolio.’ Evoke Pharma is not a large company by global standards. It has a m...
Seeking AlphaMar 4
Evoke Pharma receives preliminary FDA communication on Gimoti NDA; shares down 51% premarket
Evoke Pharma (NASDAQ:EVOK) has received a multi-disciplinary review (DR) letter from the FDA in association with the Gimoti 505(b)(2) NDA. A DR letter is used to convey preliminary thoughts on deficiencies identified during the initial stage of NDA review. The letter described concerns in three sections: Chemistry; Clinical and Clinical Pharmacology not within the parameters for bioequivalence for abbreviated NDAs. The Company plans to respond to the deficiencies raised in the DR letter to allow time for...
Expected May 13, Pre-Market